Tag: respiratory drug delivery market insights

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Pulmonary Or Respiratory Drug Delivery Industry Expected To Reach By 2029, Starting From 2025 Levels?

The pulmonary or respiratory drug delivery market has experienced substantial expansion in recent years. Its valuation is anticipated to climb from $69.83 billion in 2024 to $75.67 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.4%. This historical growth stems from factors including the increasing prevalence of asthma, enhanced adoption of advanced inhalation devices, a worldwide increase in healthcare spending, elevated awareness regarding respiratory conditions, and a growing occurrence of allergic conditions.

Significant expansion is anticipated for the pulmonary or respiratory drug delivery market in the coming years. This market is projected to reach $105.32 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.6%. This growth during the projected period stems from increased demand for personalized medicine, a higher incidence of chronic respiratory conditions, a stronger focus on telemedicine, greater investments in healthcare infrastructure, and the expansion of e-commerce for pharmaceutical goods. Key trends expected within this period involve innovations in particle engineering, the creation of sophisticated nebulizers, the emergence of liposomal formulations, progress in computational fluid dynamics, and the introduction of smart inhalers.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

What Are The Main Drivers Boosting The Pulmonary Or Respiratory Drug Delivery Industry’s Expansion?

The rising incidence of pneumonia is anticipated to stimulate future expansion in the pulmonary or respiratory drug delivery market. Pneumonia, a lung infection, leads to inflammation of the air sacs, potentially causing them to fill with fluid or pus, resulting in symptoms such as coughing, fever, and impaired breathing. The growing occurrence of pneumonia is linked to factors including aging populations, compromised immune systems, respiratory infections, atmospheric pollution, smoking, and the emergence of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery assists individuals suffering from pneumonia by administering medications, like antibiotics, bronchodilators, or anti-inflammatory agents, straight to the lungs. This facilitates more rapid and potent treatment, easing symptoms, diminishing inflammation, eradicating infections, and enhancing lung function, thereby improving recuperation and averting complications. For example, data from November 2023, provided by the Centre for Tropical Medicine and Global Health, a UK-based leader in healthcare research, indicated a substantial increase in pneumonia cases in Kenya, reaching 793,864 during 2022/2023. Consequently, the expanding incidence of pneumonia is a key driver for the pulmonary or respiratory drug delivery market.

What Are The Primary Types Of Segments Analyzed In The Pulmonary Or Respiratory Drug Delivery Market?

The pulmonary or respiratory drug delivery market covered in this report is segmented –

1) By Product: Formulation Type, Device Type

2) By Canister Type: Plain Canister, Coated Canister

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications

4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

What Trends Are Redefining The Pulmonary Or Respiratory Drug Delivery Market Dynamics?

Major companies in the pulmonary or respiratory drug delivery market are increasingly focusing on technological advancements, such as complex drug delivery systems, to improve treatment efficacy and patient compliance. These advanced technologies enhance the targeted delivery and controlled release of therapeutic agents, leading to better drug efficacy and patient outcomes. For instance, in July 2023, Viatris Inc., a US-based healthcare company manufacturing generic and branded medicines, along with Kindeva Drug Delivery L.P., a US-based company providing drug delivery services, introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhalation aerosol, approved by the Food and Drug Administration, a US-based government agency, is the first generic version of AstraZeneca’s Symbicort. It is a metered-dose inhaler combining budesonide and formoterol, used for treating asthma and chronic obstructive pulmonary disease, and is available in two strengths: 80 micrograms and 160 micrograms, each with 4.5 micrograms of formoterol.

Which Industry Leaders Are Driving Innovation Across The Pulmonary Or Respiratory Drug Delivery Market?

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

What Regional Growth Trends Are Shaping The Pulmonary Or Respiratory Drug Delivery Market Outlook?

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Pulmonary Or Respiratory Drug Delivery Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp

Browse Through More Reports Similar to the Global Pulmonary Or Respiratory Drug Delivery Market 2025, By The Business Research Company

Pulmonary Arterial Hypertension Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Idiopathic Pulmonary Fibrosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Pulmonary Or Respiratory Drug Delivery Market Valuation Change Between Now And 2029?

The market for pulmonary or respiratory drug delivery has seen a robust growth in the recent past. The market value, which is projected to be $69.83 billion in 2024, is expected to increase to $75.67 billion in 2025, with a compound annual growth rate (CAGR) of 8.4%. The historical growth trend is mainly due to an increased incidence of asthma, the use of more sophisticated inhalation devices, a global surge in healthcare spending, heightened awareness about respiratory ailments, and a growing occurrence of allergic conditions.

The market size of pulmonary or respiratory drug delivery is predicted to witness robust expansion in the coming years. It is set to reach “$105.32 billion by 2029, with a compound annual growth rate (CAGR) of 8.6%. This surge during the projected period can be ascribed to factors like the escalating demand for individualized medication, the increasing instances of chronic respiratory conditions, intensifying focus on telemedicine, augmented investments in the healthcare sector’s infrastructure, and the expansion of e-commerce for pharmaceutical items. The forecast period will also see major trends such as advancements in particle engineering, the creation of advanced nebulizers, the evolution of liposomal formulations, progressions in computational fluid dynamics, and the establishment of smart inhalers.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

Which Factors Are Steering Growth In The Pulmonary Or Respiratory Drug Delivery Market?

The escalating occurrence of pneumonia is projected to fuel the expansion of the pulmonary or respiratory drug delivery market in the future. Pneumonia, a lung affliction, results in the inflammation of air sacs and these can then be filled with fluid or pus, which can lead to symptoms such as coughing, fever, and difficulty in breathing. The uptick in pneumonia cases can be attributed to factors such as elderly populations, diminished immune systems, respiratory infections, air pollution, smoking, and the prevalence of bacteria resistant to antibiotics. Pulmonary or respiratory drug delivery aids individuals with pneumonia by directly focusing medicine, like antibiotics, bronchodilators, or anti-inflammatory agents, on the lungs. This results in a quicker and more potent treatment that can relieve symptoms, decrease inflammation, get rid of infections, and enhance respiratory functionality, all of which can augment recovery and inhibit complications. For illustration, as reported by the Centre for Tropical Medicine and Global Health, a prominent health research institution based in the UK, there was a significant growth in pneumonia cases in Kenya, which climbed up to 793,864 in 2022/2023 during November 2023. Consequently, the growth in pneumonia cases propels the pulmonary or respiratory drug delivery market.

Which Segments Define The Structure Of The Pulmonary Or Respiratory Drug Delivery Market?

The pulmonary or respiratory drug delivery market covered in this report is segmented –

1) By Product: Formulation Type, Device Type

2) By Canister Type: Plain Canister, Coated Canister

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications

4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

What Strategic Shifts And Innovations Are Influencing The Pulmonary Or Respiratory Drug Delivery Market?

Leading organizations in the pulmonary or respiratory drug delivery market are prioritizing advancements in technology, such as complex drug delivery systems, to boost the effectiveness of treatments and patient compliance. These systems are cutting-edge technologies designed to enhance the targeted provision and controlled release of therapeutic agents, leading to improved drug efficacy and patient outcomes. For example, in July 2023, U.S. healthcare company Viatris Inc., which produces generic and branded medicines, along with Kindeva Drug Delivery L.P., a US company specializing in drug delivery, introduced Breyna Inhalation Aerosol. Approved by the Food and Drug Administration, a U.S. government agency, this inhalation aerosol is the first generic version of AstraZeneca’s Symbicort. It’s a metered-dose inhaler that integrates budesonide and formoterol for the treatment of asthma and chronic obstructive pulmonary disease. Breyna is available in concentrations of 80 and 160 micrograms, combined with 4.5 micrograms of formoterol.

Who Are The Global Leaders Steering The Pulmonary Or Respiratory Drug Delivery Market Forward?

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

What Regional Factors Are Accelerating Growth In The Pulmonary Or Respiratory Drug Delivery Market?

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Are the Latest Market Insights for the Biologics CDMO Industry?#_x000D_

In recent years, the market size for pulmonary or respiratory drug delivery has witnessed a substantial increase. It is projected to escalate from $69.83 billion in 2024 to $75.67 billion in 2025, with a compound annual growth rate (CAGR) of 8.4%. This surge during the historic period is due to factors such as the growing prevalence of asthma, increased acceptance of advanced inhalation devices, global expansion in healthcare spending, heightened awareness regarding respiratory diseases, and the escalating occurrence of allergic conditions._x000D_

_x000D_

In the coming years, considerable growth is anticipated in the market size for pulmonary or respiratory drug delivery. The market is projected to reach “$105.32 billion in 2029, expanding at a compound annual growth rate (CAGR) of 8.6%.” The forecasted expansion can be linked to factors such as increased interest in personalized medicine, rising chronic respiratory disease rates, growing focus on telemedicine, a surge in healthcare infrastructure investments, and e-commerce growth in the pharmaceutical sector. Key trends anticipated during the forecast period include progress in particle engineering, the emergence of sophisticated nebulizers, liposomal formulation development, advances in computational fluid dynamics, and creation of intelligent inhalers._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Biologics CDMO Industry?#_x000D_

The biologic CDMO market is anticipated to grow due to the increasing demand for cell and genetic therapy. These innovative medical strategies use living cells or genetic material to address disease causes at the cellular or genetic level. They provide potential remedies for conditions otherwise difficult to treat or cure with conventional medications. The rising demand for these therapies is attributed to their groundbreaking approach in disease treatment, tackling underlying genetic or cellular causes. Biologic CDMOs offer expertise in dealing with living cells, viral vectors, and genetic material. They promote safe and effective production of cell and gene therapies and assist biopharmaceutical companies in meeting regulatory standards and technical obstacles, hence promoting the transition from research to clinical application. For example, The American Society of Gene & Cell Therapy (ASGCT), a top professional membership organization based in the U.S., reported in January 2023 that the gene, cell, and RNA therapy pipeline experienced a 7% growth in 2022, reaching a total of 3,726 therapies under development. Among these, 55% are gene therapies, 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Thus, the rising demand for cell and genetic therapy is fueling the growth of the biologic CDMO market._x000D_

_x000D_

_x000D_

The pulmonary or respiratory drug delivery market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Formulation Type, Device Type_x000D_

2) By Canister Type: Plain Canister, Coated Canister_x000D_

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications_x000D_

4) By End-User: Hospitals, Clinics, Home Care Settings_x000D_

_x000D_

Subsegments:_x000D_

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays _x000D_

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices _x000D_

_x000D_

#What Notable Trends Are Shaping The Direction Of The Biologics CDMO Market?#_x000D_

Technological advancements in complex drug delivery systems are the main focus of leading companies in the pulmonary or respiratory drug delivery market as these improvements increase the effectiveness of treatments and patient adherence. These high-tech systems heighten the precise delivery and regulated release of therapeutic substances, which in turn boost drug effectiveness and patient health. An example of this is when Viatris Inc., a US firm that produces generic and branded medicines, and Kindeva Drug Delivery L.P., an American company that specializes in drug delivery, introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol in July 2023. This inhalation aerosol, which has been approved by the US government agency, the Food and Drug Administration, is the first generic version of AstraZeneca’s Symbicort, and is a metered-dose inhaler combining budesonide and formoterol. It’s designed for treating asthma and chronic obstructive pulmonary disease and comes in two strengths: 80 micrograms and 160 micrograms, each containing 4.5 micrograms of formoterol._x000D_

_x000D_

#Who Are The Primary Players Operating Across The Global Biologics CDMO Market?#_x000D_

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc _x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report_x000D_

_x000D_

#Which Region Offers The Most Growth Potential For The Biologics CDMO Market Through 2029?#_x000D_

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Are the Projected Market Size and Growth Rates for the Pulmonary Or Respiratory Drug Delivery Market From 2025 To 2029?#_x000D_

The market size for drug delivery in the pulmonary or respiratory sector has experienced a robust growth over the last few years. The market is projected to witness an increase from $69.83 billion in 2024 to $75.67 billion in 2025, with a compound annual growth rate (CAGR) of 8.4%. This significant expansion during the historic period could be tied to various factors, such as the escalating cases of asthma, a surge in the incorporation of innovative inhalation equipment, an uptick in global healthcare investment, growing knowledge about respiratory illnesses, and an increasing incidence of allergy-related conditions._x000D_

_x000D_

The market for the delivery of pulmonary or respiratory drugs is forecasted to experience significant expansion in the coming years. The market is set to reach a valuation of $105.32 billion by 2029, with an annual growth rate (CAGR) of 8.6%. The predicted growth throughout the forecast period can be accredited to factors such as the increasing demand for custom-made medicine, a growing number of chronic respiratory disease cases, a heightened focus on telemedicine, escalating investments in the healthcare sector, and the expansion of e-commerce for pharma products. Key market trends during the forecast period encompass progress in particle engineering, the creation of advanced nebulizers, the development of liposomal formulations, advancements in computational fluid dynamics, and the introduction of smart inhalers._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp_x000D_

_x000D_

#What Are the Major Market Drivers Behind the Rising Adoption of Pulmonary Or Respiratory Drug Delivery Market?#_x000D_

The rise in occurrences of pneumonia is anticipated to spur the advancement of the pulmonary or respiratory drug delivery market. Pneumonia, a lung disease causing inflammation in the air sacs that can be filled with fluid or pus, results in symptoms including coughing, fever, and breathing difficulties. Factors contributing to the increased prevalence of pneumonia include ageing populations, compromised immune systems, respiratory infections, air pollution, smoking, and the emergence of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery provides a direct route to the lungs for medications like antibiotics, bronchodilators, or anti-inflammatory drugs, enabling quicker and more efficacious treatment. This helps to mitigate symptoms, lessen inflammation, eradicate infections, and enhance respiratory function, thereby improving recovery and averting complications. Evidence for this trend came from the Centre for Tropical Medicine and Global Health in the UK, who reported that in November 2023 pneumonia cases in Kenya saw a sizeable increase, reaching 793,864 in 2022/2023. Consequently, the escalating rate of pneumonia propels the pulmonary or respiratory drug delivery market._x000D_

_x000D_

#Which Key Market Segments Comprise the Pulmonary Or Respiratory Drug Delivery Market and Drive Its Revenue Growth?#_x000D_

The pulmonary or respiratory drug delivery market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Formulation Type, Device Type_x000D_

2) By Canister Type: Plain Canister, Coated Canister_x000D_

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications_x000D_

4) By End-User: Hospitals, Clinics, Home Care Settings_x000D_

_x000D_

Subsegments:_x000D_

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays _x000D_

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices _x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Pulmonary Or Respiratory Drug Delivery Market Expansion Across the Globe?#_x000D_

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Strategic Trends Steering thePulmonary Or Respiratory Drug Delivery Market Direction?#_x000D_

Key players in the respiratory drug delivery market are prioritizing technological innovations, such as intricate drug delivery mechanisms, to augment treatment effectiveness and patient compliance. These sophisticated delivery systems harness cutting-edge technology to amplify targeted drug delivery and controlled release of medications, thereby enhancing the efficacy of the drugs and patient outcomes. For instance, in July 2023, VIatris Inc, a US healthcare company specializing in generic and branded medications, in conjunction with Kindeva Drug Delivery L.P., a company specializing in drug delivery systems, launched an inhalation aerosol named Breyna (budesonide and formoterol fumarate dihydrate). This was approved by the US Food and Drug Administration and marks the first generic of AstraZeneca’s Symbicort. It is a metered-dose inhaler that coalesces budesonide and formoterol to treat asthma and chronic obstructive pulmonary disease, available in strengths of 80 and 160 micrograms and includes 4.5 micrograms of formoterol._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report_x000D_

_x000D_

#How Is the Pulmonary Or Respiratory Drug Delivery Market Conceptually Defined?#_x000D_

Pulmonary or respiratory drug delivery refers to the administration of medication directly into the lungs to achieve rapid absorption, targeted treatment, and reduced systemic side effects for both local and systemic therapeutic effects._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pulmonary Or Respiratory Drug Delivery Market Size Changed, over the years?

There has been robust growth in the market size for pulmonary or respiratory drug delivery in the recent years. It is projected to expand from a value of $69.83 billion in 2024 to a bigger value of $76.38 billion in 2025, with a compound annual growth rate (CAGR) hitting 9.4%. Factors that fueled the growth during the historic period include a surge in asthma cases, increased uptake of cutting-edge inhalation devices, global hike in healthcare spending, heightened knowledge about respiratory diseases, and a mounting number of allergy-related conditions.

How Much Will the Pulmonary Or Respiratory Drug Delivery Market Be Worth in 2029?

The market for pulmonary or respiratory drug delivery is poised to experience robust growth in the coming years with the market size predicted to rise to $107.85 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.0%. This significant growth during the projected period is due to factors such as the surge in demand for personalized healthcare, the increasing cases of chronic respiratory diseases, heightened focus on telemedicine, escalated investment in healthcare infrastructure, and the expansion of e-commerce in the pharmaceutical sector. Additionally, key trends to watch in this period include evolving particle engineering technology, the creation of more advanced nebulizers, the development of liposomal formulations, improvements in computational fluid dynamics, and the emergence of smart inhalers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

Which is the Largest Company in the Pulmonary Or Respiratory Drug Delivery Market?

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

What Are the Main Market Drivers in the Pulmonary Or Respiratory Drug Delivery Industry?

The rise in pneumonia cases is predicted to contribute to the expansion of the pulmonary or respiratory drug delivery market. Pneumonia, a lung infection causing inflammation and potentially fluid or pus in the air sacs, results in symptoms like coughing, fever, and difficulty in breathing. Factors such as aging populations, weakened immune systems, respiratory infections, air pollution, smoking, and the increasing prevalence of antibiotic-resistant bacteria significantly contribute to the escalation of pneumonia cases. The application of pulmonary or respiratory drugs provides a direct target to the lungs with medications like antibiotics, bronchodilators, or anti-inflammatory agents. This facilitates faster and more efficient treatments, mitigating symptoms, reducing inflammation, eradicating infections, and enhancing respiratory function, thereby expediting recovery and averting complications. For example, in November 2023, the Centre for Tropical Medicine and Global Health, a prominent leader in healthcare research based in the UK, reported a substantial rise in pneumonia cases in Kenya, registering 793,864 in 2022/2023. Hence, the growing incidence of pneumonia fuels the progression of the pulmonary or respiratory drug delivery market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp

How Is the Pulmonary Or Respiratory Drug Delivery Market Segments Structured?

The pulmonary or respiratory drug delivery market covered in this report is segmented –

1) By Product: Formulation Type, Device Type

2) By Canister Type: Plain Canister, Coated Canister

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications

4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

What Strategic Trends Are Transforming the Pulmonary Or Respiratory Drug Delivery Market?

In the pulmonary or respiratory drug delivery market, key players are emphasizing the importance of technological advancements like sophisticated drug delivery systems to increase treatment effectiveness and patient adherence. These sophisticated drug delivery systems are cutting-edge technologies that amplify the targeted delivery and controlled release of medicinal agents, heightening drug effectiveness and patient results. For example, Viatris Inc., a US healthcare company producing generic and branded drugs, and Kindeva Drug Delivery L.P., a US corporation offering drug delivery, launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol in July 2023. It was approved by the FDA, a US government agency, making it the first generic version of AstraZeneca’s Symbicort and a metered-dose inhaler combining budesonide and formoterol for the treatment of asthma and chronic obstructive pulmonary disease. It comes in two strengths, 80 micrograms, and 160 micrograms, with 4.5 micrograms of formoterol.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

Which Global Regions Offer the Highest Growth in the Pulmonary Or Respiratory Drug Delivery Market?

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939

This Report Delivers Insight On:

1. How big is the pulmonary or respiratory drug delivery market, and how is it changing globally?

2. Who are the major companies in the pulmonary or respiratory drug delivery market, and how are they performing?

3. What are the key opportunities and risks in the pulmonary or respiratory drug delivery market right now?

4. Which products or customer segments are growing the most in the pulmonary or respiratory drug delivery market?

5. What factors are helping or slowing down the growth of the pulmonary or respiratory drug delivery market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

How Has The Pulmonary Or Respiratory Drug Delivery Market Size Shifted, And What Is the Outlook Through 2034?

Over the past few years, there has been a significant growth in the market size of pulmonary and respiratory drug delivery. The market worth is projected to rise from $69.83 billion in 2024 to an estimated $76.38 billion in 2025, marking a compound annual growth rate (CAGR) of 9.4%. Factors such as augmented asthma prevalence, enhanced adoption of cutting-edge inhalation devices, global healthcare expenditure escalation, increased consciousness about respiratory illnesses, and the rising occurrence of allergy-related conditions have all contributed to the historical growth period.

The market size for respiratory or pulmonary drug delivery is predicted to experience substantial expansion in the coming years. By 2029, it is forecasted to reach an impressive value of $107.85 billion, with a compound annual growth rate (CAGR) of 9.0%. This anticipated growth during the outlook period can be attributed to several factors such as the growing demand for personalized medicine, an increase in chronic respiratory diseases, a heightened focus on telemedicine, increased investment in healthcare infrastructure, and e-commerce growth in the pharmaceutical sector. Noteworthy trends for this period include advancements in particle engineering, creation of cutting-edge nebulizers, liposomal formulation development, progress in computational fluid dynamics, and the emergence of smart inhalers.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

What Are the Core Market Drivers Propelling Growth in the Pulmonary Or Respiratory Drug Delivery Industry?

The growth of the pulmonary or respiratory drug delivery market is anticipated to be spurred by the rising incidence of pneumonia. This disease, a lung infection, causes the air sacs to inflame and potentially fill with fluid or pus, leading to symptoms such as coughing, fever, and breathing difficulties. Factors contributing to an increased prevalence of pneumonia include an aging population, compromised immunity systems, respiratory infections, pollution, smoking, and the emergence of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery provides a more direct targeting of the lungs, delivering medications like antibiotics, bronchodilators, or anti-inflammatory agents more efficiently. This promotes faster and more effective treatment, easing symptoms, reducing inflammation, clearing infections, and enhancing respiratory function, and ultimately improving recovery and reducing complications. For instance, pneumonia cases in Kenya rose sharply to 793,864 in 2022/2023, according to a November 2023 report from the Centre for Tropical Medicine and Global Health, a healthcare research leader based in the UK. Hence, the market for pulmonary or respiratory drug delivery is being driven by the increasing incidence of pneumonia.

How Is the Pulmonary Or Respiratory Drug Delivery Market Segmented?

The pulmonary or respiratory drug delivery market covered in this report is segmented –

1) By Product: Formulation Type, Device Type

2) By Canister Type: Plain Canister, Coated Canister

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications

4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp

Which Regions Are Driving the Next Phase of the Pulmonary Or Respiratory Drug Delivery Market Growth?

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Pulmonary Or Respiratory Drug Delivery Market?

Leading businesses within the pulmonary and respiratory drug delivery market are emphasizing on technological innovations such as sophisticated drug delivery systems to improve treatment effectiveness and patient adherence. These cutting-edge systems amplify the localized delivery and controlled release of medicinal substances, thereby enhancing drug potency and patient health outcomes. For example, in July 2023, American healthcare company, Viatris Inc., known for producing generic and branded medication and Kindeva Drug Delivery L.P., also a US-based firm that specializes in drug delivery, introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhalation aerosol gained approval from the Food and Drug Administration, a government agency in the US. This is considered the first generic equivalent to AstraZeneca’s Symbicort and it’s also a metered-dose inhaler that blends budesonide and formoterol for the management of asthma and chronic obstructive pulmonary disease. The product is available in two concentrations of 80 micrograms and 160 micrograms, supplemented by 4.5 micrograms of formoterol.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

How Is the Pulmonary Or Respiratory Drug Delivery Market Defined and What Are Its Core Parameters?

Pulmonary or respiratory drug delivery refers to the administration of medication directly into the lungs to achieve rapid absorption, targeted treatment, and reduced systemic side effects for both local and systemic therapeutic effects.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of thePulmonary Or Respiratory Drug Delivery Market?

The pulmonary or respiratory drug delivery market is being propelled by the rising incidences of pneumonia. This lung infection causes inflammation of air sacs, which may become filled with fluid or pus, resulting in symptoms such as cough, fever, and difficulty in breathing. Factors such as aging populations, compromised immune systems, respiratory infections, air pollution, smoking, and the emergence of antibiotic-resistant bacteria contribute to the increasing cases of pneumonia. Pulmonary or respiratory drug delivery aids patients with pneumonia by specifically targeting the lungs with treatments like antibiotics, bronchodilators, or anti-inflammatory agents, in turn, offering quicker and more efficient relief from symptoms, reducing inflammation, eliminating infections, and improving respiratory function. This ultimately leads to improved recovery rates and reduced complications. The Centre for Tropical Medicine and Global Health, a UK-based healthcare research leader, reported in November 2023 that the number of pneumonia cases in Kenya climbed significantly, hitting 793,864 cases in 2022/2023. As a result, the rising occurrence of pneumonia fuels the growth of the pulmonary or respiratory drug delivery market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

#What Long-Term Growth Rate is Expected for thePulmonary Or Respiratory Drug Delivery Market Between 2025 and 2034?

The market size for pulmonary or respiratory drug delivery has seen considerable growth in the recent past. The market, which was worth $69.83 billion in 2024, is projected to rise to $76.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this growth during the historical period include a rise in the prevalence of asthma, increased uptake of innovative inhalation devices, a global increase in healthcare spending, enhanced awareness of respiratory diseases, and an uptick in the occurrence of allergic conditions.

The market size of pulmonary or respiratory drug delivery is predicted to experience significant growth in the forthcoming years, rising to $107.85 billion in 2029 with a compound annual growth rate (CAGR) of 9.0%. The projected growth during this period is due to factors such as the increasing demand for personalized medicine, the expanding incidence of chronic respiratory illnesses, the emphasis on telemedicine, increasing investment in the healthcare infrastructure, and the growth of e-commerce in the pharmaceutical sector. Key trends expected during this period include the improvement in particle engineering, the production of advanced nebulizers, the creation of liposomal formulations, advances in computational fluid dynamics, and the development of smart inhalers.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939

What Key Market Trends and Innovations Are Shaping the Future of thePulmonary Or Respiratory Drug Delivery Industry?

In the pulmonary or respiratory drug delivery market, prominent companies are highlighting innovations like advanced drug delivery systems to improve the effectiveness of treatments and patient adherence. Advanced drug delivery systems are state-of-the-art solutions designed to enhance the precise delivery and controlled release of medical treatments, which in turn boosts their effectiveness and patient results. Take for example, in July 2023, Viatris Inc., an American healthcare business that produces generic and branded medications, partnered with Kindeva Drug Delivery L.P., a US firm specializing in drug delivery, to introduce Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhalation aerosol was sanctioned by the Food and Drug Administration, a U.S. government institution. Marking the first generic model of AstraZeneca’s Symbicort, this metered-dose inhaler amalgamates budesonide and formoterol for the management of asthma and chronic obstructive pulmonary disease. It can be found in two potencies, specifically 80 micrograms and 160 micrograms, along with 4.5 micrograms of formoterol.

Which Companies Are Leading the Charge in Expanding thePulmonary Or Respiratory Drug Delivery Market Growth?

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

How is the Global Pulmonary Or Respiratory Drug Delivery Market Segemented?

The pulmonary or respiratory drug delivery market covered in this report is segmented –

1) By Product: Formulation Type, Device Type

2) By Canister Type: Plain Canister, Coated Canister

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications

4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp

Which Geographics are Influencing the Growth of the Pulmonary Or Respiratory Drug Delivery Market?

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Pulmonary Or Respiratory Drug Delivery Market 2025, By The Business Research Company:

Pulmonary Arterial Hypertension Global Market Report 2025

https://thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Idiopathic Pulmonary Fibrosis Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the pulmonary or respiratory drug delivery market grown in recent years?

In recent times, the size of the pulmonary or respiratory drug delivery market has witnessed robust growth. It is expected to increase from $69.83 billion in 2024 to $76.38 billion in 2025 with a compound annual growth rate (CAGR) of 9.4%. The increasing occurrence of asthma, the growing use of advanced inhalation devices, the global expansion in healthcare spending, heightened awareness of respiratory illnesses, and the increasing rate of allergies are key factors that contributed to market growth in the historic period.

How is the pulmonary or respiratory drug delivery market size expected to evolve during the forecast period?

The market size for pulmonary or respiratory drug delivery is anticipated to witness substantial growth in the forthcoming years. By 2029, it is expected to escalate to $107.85 billion, expanding at a compound annual growth rate (CAGR) of 9.0%. Various factors contributing to this anticipated growth during the projection period include increased demand for individualized treatment, higher incidence of long-term respiratory illnesses, rising focus on telehealth, amplified healthcare infrastructure investments, and e-commerce expansion for pharmaceutical goods. The forecast period is also set to see emerging trends such as progress in particle engineering, enhanced nebulizer developments, evolution of liposomal formulations, advancements in computational fluid dynamics, and the introduction of intelligent inhalers.

Get your pulmonary or respiratory drug delivery market report here!

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

Which key drivers are propelling the pulmonary or respiratory drug delivery market’s growth?

The growth of the pulmonary or respiratory drug delivery market is predicted to be spurred by the rising incidence of pneumonia. Pneumonia manifests as a lung infection, resulting in the inflammation of air sacs and possibly leading to accumulation of fluid or pus, which can cause fever, cough, and difficulties in breathing. There is an escalation in pneumonia prevalence due to factors including ageing demographics, compromised immune systems, respiratory infections, air pollution, smoking, and burgeoning antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery provides beneficial aid to pneumonia patients by delivering medications such as antibiotics, bronchodilators, and anti-inflammatory drugs directly to the lungs. This targeted approach promotes quicker and more effective symptom relief, inflammation reduction, infection clearance and enhancement of respiratory functionality, aiding in an accelerated recovery while thwarting any potential complications. For example, as stated by the Centre for Tropical Medicine and Global Health, a UK healthcare research leader, pneumonia cases in Kenya noticed a huge leap, with the count touching 793,864 in 2022/2023 in November 2023. As such, the escalating numbers of pneumonia patients propels the growth of the pulmonary or respiratory drug delivery market.

What are the market segments in the pulmonary or respiratory drug delivery industry?

The pulmonary or respiratory drug delivery market covered in this report is segmented –

1) By Product: Formulation Type, Device Type

2) By Canister Type: Plain Canister, Coated Canister

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications

4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

Which leading companies are shaping the growth of the pulmonary or respiratory drug delivery market?

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

What emerging trends are influencing the growth of the pulmonary or respiratory drug delivery market?

Major companies operating in the pulmonary or respiratory drug delivery market are focusing on technological advancements such as complex drug delivery systems that enhance treatment efficacy and patient compliance. Complex drug delivery systems are advanced technologies that enhance the targeted delivery and controlled release of therapeutic agents, improving drug efficacy and patient outcomes. For instance, in July 2023, Viatris Inc., a US-based healthcare company that manufactures generic and branded medicines and Kindeva Drug Delivery L.P., a US-based company that offers drug delivery launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, an inhalation aerosol approved by the Food and Drug Administration, a US-based government agency. This is the first generic version of AstraZeneca’s Symbicort and a metered-dose inhaler that combines budesonide and formoterol for treating asthma and chronic obstructive pulmonary disease. It is available in two strengths of 80 micrograms and 160 micrograms with 4.5 micrograms of formoterol.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939

Which geographic areas are influencing the growth of the pulmonary or respiratory drug delivery market?

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Pulmonary Arterial Hypertension Global Market Report 2025

https://thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Idiopathic Pulmonary Fibrosis Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Rapidly is the Pulmonary Or Respiratory Drug Delivery Market Expected to Expand Between 2025 and 2034 Based on Current Trends?

There has been a robust expansion in the market size of pulmonary or respiratory drug delivery in the past few years. It is projected to increase from $69.83 billion in 2024 to $76.38 billion in 2025, which equates to a compound annual growth rate (CAGR) of 9.4%. The historical growth of this market is largely due to factors such as the increasing occurrence of asthma, widespread adoption of sophisticated inhalation devices, global increase in healthcare spending, growing awareness about respiratory diseases, and a surge in the number of reported allergic conditions.

The market size of pulmonary or respiratory drug delivery is forecasted to experience robust growth in the coming years. The market is projected to expand to $107.85 billion by 2029, with a compound annual growth rate (CAGR) of 9.0%. The surge during the forecast period could be due to the increasing demand for tailor-made medicine, the growing incidence of chronic respiratory diseases, a heightened focus on telemedicine, an escalation in investments in healthcare infrastructure, and an increase in pharmaceutical product e-commerce. During the forecast period, major trends anticipated include enhancements in particle engineering, the creation of advanced nebulizers, the expansion of liposomal formulations, advancements in computational fluid dynamics, and the maturation of smart inhalers.

How Are the key drivers Contributing to the Expansion of the Pulmonary Or Respiratory Drug Delivery Market?

The escalating incidences of pneumonia are projected to fuel the expansion of the pulmonary or respiratory drug delivery market. Pneumonia, a lung infection, inflames the air sacs and can cause a build-up of fluid or pus, resulting in symptoms such as cough, fever, and breathlessness. The surge in pneumonia incidences can be attributed to factors like aging populations, compromised immune systems, respiratory infections, air pollution, smoking, and the emergence of antibiotic-resistant bacteria. The pulmonary or respiratory drug delivery approach aids pneumonia patients by directly delivering medications such as antibiotics, bronchodilators, or anti-inflammatory agents to the lungs. This enables a swifter and more potent treatment protocol to alleviate symptoms, curb inflammation, clear infections, and enhance respiratory performance, ultimately leading to quicker recovery and the avoidance of complications. For example, the Centre for Tropical Medicine and Global Health, a UK-based pioneer in healthcare research, indicated a significant surge in pneumonia cases in Kenya in November 2023, touching 793,864 in 2022/2023. Hence, the escalating incidences of pneumonia act as a driving force for the pulmonary or respiratory drug delivery market.

Get Your Free Sample of the Global Pulmonary Or Respiratory Drug Delivery Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

Which Key Players Are Shaping the Future of the Pulmonary Or Respiratory Drug Delivery Market?

Major companies operating in the pulmonary or respiratory drug delivery market are:

• Merck & Co. Inc._x000D_

• Novartis AG_x000D_

• Thermo Fisher Scientific Inc._x000D_

• AstraZeneca plc_x000D_

• Abbott Laboratories_x000D_

How Are the Latest Trends Influencing the Growth of the Pulmonary Or Respiratory Drug Delivery Market?

Key players in the market of pulmonary or respiratory drug delivery are centering their efforts on technological improvements like intricate drug delivery systems to maximize treatment effectiveness and patient adherence. These complex systems are a breakthrough in technology, optimizing targeted delivery alongside controlled therapeutic agent release that augments drug efficacy as well as patient prognosis. An example of this is seen in July 2023, when Viatris Inc., an American healthcare firm that produces generic and branded drugs, partnered with Kindeva Drug Delivery, L.P., another American firm specializing in drug delivery, to introduce Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhalation aerosol gained approval from the US government’s Food and Drug Administration as the inaugural generic version of AstraZeneca’s Symbicort, a metered-dose inhaler merging budesonide and formoterol, used in the therapy of asthma and chronic obstructive pulmonary disease. Breyna is offered in two potencies – 80 micrograms and 160 micrograms, with formoterol comprising 4.5 micrograms.

Get Instant Access to the Global Pulmonary Or Respiratory Drug Delivery Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

What Are the Major Segments of the Pulmonary Or Respiratory Drug Delivery Market and Their Role in Driving Growth?

The pulmonary or respiratory drug delivery market covered in this report is segmented –

1) By Product: Formulation Type, Device Type

2) By Canister Type: Plain Canister, Coated Canister

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications

4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

What Regions Are At the Forefront of Pulmonary Or Respiratory Drug Delivery Market Expansion?

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Can We Define the Pulmonary Or Respiratory Drug Delivery Market and Its Key Components?

Pulmonary or respiratory drug delivery refers to the administration of medication directly into the lungs to achieve rapid absorption, targeted treatment, and reduced systemic side effects for both local and systemic therapeutic effects.

Browse Through More Similar Reports By The Business Research Company:

Pulmonary Arterial Hypertension Global Market Report 2025

https://thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Idiopathic Pulmonary Fibrosis Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: